Skip to main content

Animations

MJFF Publications

2531 - 2540 of 8761 Results
Title
Year
  • Year
  • 2020
  • 2020
  • 2023
  • 2013
  • 2021
  • 2016
  • 2013
  • 2025
  • 2021
  • 2024
  • Summary Details
    OPEN
    Title: Screening peripheral biopsies for alpha‐synuclein pathology using deep machine learning
    Journal Name: Alzheimer's & Dementia
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/alz.047358
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Association of MAPT subhaplotypes with clinical and demographic features in Parkinson’s disease
    Journal Name: Annals of Clinical and Translational Neurology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/acn3.51139
    Citation Count: 10
  • Summary Details
    OPEN
    Title: Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease
    Journal Name: Experimental Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.expneurol.2023.114370
    Citation Count: 13
  • Summary Details
    OPEN
    Title: Diabetes is associated with postural instability and gait difficulty in Parkinson disease
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2013.01.016
    Citation Count: 108
  • Summary Details
    OPEN
    Title: The effects of mood and cognition on daily functioning and quality of life in older people living with HIV and people with Parkinson’s disease.
    Journal Name: Neuropsychology
    Publisher: American Psychological Association (APA)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: other-oa
    DOI - Digital Object Identifier: 10.1037/neu0000760
    Citation Count: 2
  • Summary Details
    RESTRICTED
    Title: A Phase 2A Trial of the Novel mGluR5‐Negative Allosteric Modulator Dipraglurant for Levodopa‐Induced Dyskinesia in Parkinson's Disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mds.26659
    Citation Count: 130
  • Summary Details
    OPEN
    Title: Pooled analysis of iron-related genes in Parkinson's disease: Association with transferrin
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.nbd.2013.09.019
    Citation Count: 78
  • Summary Details
    OPEN
    Title: Non-Motor Symptoms as Markers of Disease Severity in Parkinson’s Disease: Associations Between Constipation, Depression, REM Sleep Behavior Disorder, and Motor Impairment
    Journal Name: Biomedicines
    Publisher: MDPI AG
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.3390/biomedicines13112704
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Modeling alpha-synuclein pathology in a human brain-chip to assess blood-brain barrier disruption
    Journal Name: Nature Communications
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41467-021-26066-5
    Citation Count: 177
  • Summary Details
    RESTRICTED
    Title: Delineating three distinct spatiotemporal patterns of brain atrophy in Parkinson’s disease
    Journal Name: Brain
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1093/brain/awae303
    Citation Count: 9
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.